Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability

AIMS: ) provides predictive information beyond the prescribed dose in a real-world cohort of patients with type 2 diabetes (T2D). MATERIALS AND METHODS: with changes in HbA1c and percent body weight, and to compare model fit. For GI side effects, time-adjusted fixed-effects logistic regression was employed. RESULTS: had greater predictive value for tolerability. CONCLUSIONS: Although estimated and not measured, the exposure to oral semaglutide may provide outcome-dependent information. While the prescribed dose seems sufficient to predict glycaemic response, estimated exposure provides additional value for weight loss and GI tolerability.